To analyze clinical outcome, local response, survival and toxicity in patients with primary cutaneous lymphoma (PCL) treated with radiotherapy.
Methods:
From 1995 to 2014, 112 patients were treated. B-cell lymphomas (CBCLs; n = 86) and T-cell lymphomas (CTCLs; n = 23) were analyzed separately. Clinical and therapeutic characteristics (age, sex, histology, primary treatment and radiotherapy modality) were related to response to treatment, survival and toxicity.
Results:
CBCLs were divided into 4 subgroups: marginal-zone lymphoma (n = 20), follicle center lymphoma (n = 32), diffuse large-cell lymphoma (DLBCL; n = 22) and DLBCL-leg type (n = 12). No significant correlation was found between doses and systemic treatments, extent of biopsy and number of lesions. DLBCL-leg type patients were older (p = 0.05), had disseminated disease (p = 0.034), and more frequently had local (p = 0.01) or systemic recurrence (p = 0.05). CTCLs were divided into 4 subgroups: α/β CTCL (n = 3), nasal type CTCL (n = 0), γ/δ CTCL (n = 10) and mycosis fungoides (n = 10). Longer disease-free survival was observed in patients obtaining complete remission (p<0.001).
Conclusions:
Radiotherapy is feasible, safe and effective for localized PCLs. The choice of dose is related to histological subgroups and the related prognoses. Survival results are very good also in relapsing disease. In advanced cutaneous lymphoma radiotherapy alone has mainly a role in symptom palliation.
ConnorsJMHsiEDFossFM. Lymphoma of the skin. Hematology (Am Soc Hematol Educ Program). 2002;2002(1):263-282.
2.
WillemzeRJaffeESBurgGet al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-3785.
3.
BradfordPTDevesaSSAndersonWFToroJR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064-5073.
GollingPCozzioADummerRFrenchLKempfW. Primary cutaneous B-cell lymphomas - clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome. Leuk Lymphoma. 2008;49(6):1094-1103.
WillemzeRHodakEZinzaniPLSpechtLLadettoM; ESMO Guidelines Working Group. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(6 Suppl 6):vi149-vi154.
8.
DuvicMHymesKHealdPet al; Bexarotene Worldwide Study GroupBexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001;19(9):2456-2471.
9.
ZinzaniPLBonthapallyVHuebnerDLutesRChiAPileriS. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: cutaneous T-cell lymphomas. Crit Rev Oncol Hematol. 2016;99:228-240.
10.
AssafCGellrichSSteinhoffMet al. Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG). J Dtsch Dermatol Ges. 2007;5(8):662-668.
11.
SenffNJNoordijkEMKimYHet al; European Organization for Research and Treatment of Cancer; International Society for Cutaneous Lymphoma. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008;112(5):1600-1609.
12.
SpechtLDabajaBIllidgeTWilsonLDHoppeRT; International Lymphoma Radiation Oncology Group. Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92(1):32-39.
FarkasAKemenyLFrenchLEDummerR. New and experimental skin-directed therapies for cutaneous lymphomas. Skin Pharmacol Physiol. 2009;22(6):322-334.
15.
KarzmarkCJLoevingerRSteeleREWeissbluthM. A technique for large-field, superficial electron therapy. Radiology. 1960;74(4):633-644.
16.
PageVGardnerAKarzmarkCJ. Patient dosimetry in the electron treatment of large superficial lesions. Radiology. 1970;94(3):635-641.
17.
ZinzaniPLQuaglinoPPimpinelliNet al; Italian Study Group for Cutaneous Lymphomas. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol. 2006;24(9):1376-1382.
18.
YsebaertLTrucGDalacSet al. Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation). Int J Radiat Oncol Biol Phys. 2004;58(4):1128-1134.
19.
SenffNJHoefnagelJJNeelisKJVermeerMHNoordijkEMWillemzeR; Dutch Cutaneous Lymphoma Group. Results of radiotherapy in 153 primary cutaneous B-cell lymphomas classified according to the WHO-EORTC classification. Arch Dermatol. 2007;143(12):1520-1526.
20.
LowryLSmithPQianWet al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100(1):86-92.
21.
KempfWPfaltzKVermeerMHet al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118(15):4024-4035.
22.
YuJBMcNiffJMLundMWWilsonLD. Treatment of primary cutaneous CD30+ anaplastic large-cell lymphoma with radiation therapy. Int J Radiat Oncol Biol Phys. 2008;70(5):1542-1545.
23.
WobserMKneitzHBröckerEBBeckerJC. Primary cutaneous diffuse large B-cell lymphoma, leg-type, treated with a modified R-CHOP immunochemotherapy – diagnostic and therapeutic challenges. J Dtsch Dermatol Ges. 2011;9(3):204-211.
24.
HeinzerlingLMUrbanekMFunkJOet al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer. 2000;89(8):1835-1844.
25.
SiegelRSPandolfinoTGuitartJRosenSKuzelTM. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol. 2000;18(15):2908-2925.
26.
TrautingerFKnoblerRWillemzeRet al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer. 2006;42(8):1014-1030.
27.
SokolLNaghashpourMGlassLF. Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management. Cancer Control. 2012;19(3):236-244.
28.
NeelisKJSchimmelECVermeerMHSenffNJWillemzeRNoordijkEM. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys. 2009;74(1): 154-158.
29.
MicailyBMiyamotoCKantorGet al. Radiotherapy for unilesional mycosis fungoides. Int J Radiat Oncol Biol Phys. 1998;42(2):361-364.
30.
WilsonLDKacinskiBMJonesGW. Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys. 1998;40(1):109-115.
31.
TseEKwongYL. How I treat NK/T-cell lymphomas. Blood. 2013;121(25):4997-5005.
MazzeoERubinoLBuglioneMet al. The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: principles and indications. Rep Pract Oncol Radiother. 2013;19(2):77-91.
34.
JonesGWKacinskiBMWilsonLDet al. Total skin electron radiation in the management of mycosis fungoides: consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol. 2002;47(3):364-370.
35.
QuirósPAJonesGWKacinskiBMet al. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys. 1997;38(5):1027-1035.
36.
HorwitzSMOlsenEADuvicMPorcuPKimYH. Review of the treatment of mycosis fungoides and Sézary syndrome: a stage-based approach. J Natl Compr Canc Netw. 2008;6(4):436-442.
